Cancer
Sort
ISB researchers reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment
A new study co-led by ISB and published in the journal Cell Reports Medicine reveals how a rare lung cancer can shift between cell types, pass through hybrid states, and build distinct tumor “neighborhoods” that may help it evade detection and resist treatment.
Researchers at the Institute for Systems Biology argue that combining systems biology, longitudinal multiomics data, and artificial intelligence could transform healthcare from reactive treatment to proactive prevention, enabling scientists and clinicians to detect early molecular signs of disease and intervene before symptoms appear.
From Nobel recognition and scientific firsts to transformative collaborations and community impact, 2025 marked one of the most significant years in ISB’s 25-year history.
Discussing Super Agers, Drs. Eric Topol and Lee Hood connected breakthroughs in genomics, AI, and lifestyle science to the pursuit of longer, healthier lives.
The pioneering work of Mary Brunkow and Fred Ramsdell began with a mysterious mutant mouse known as “scurfy,” leading them to identify the FOXP3 gene and unlock how regulatory T cells prevent autoimmune disease — discoveries that now point to new treatments in cancer and autoimmunity.